

Supplemental Amendment and Response
U.S. Serial No.: 10/072,634
Page 6 of 7

REMARKS

Claims 38, 41-43 and 74-98 have been cancelled without prejudice. Claims 37, 39, and 40 have been amended. Upon entry of this paper, claims 33, 36, 37, 39, 40, 44-54, 56-62, and 107 will be pending and under consideration.

Applicants wish to thank Examiner Mahatan for the telephonic interviews with the undersigned, which took place on October 7, 2004, October 26, 2004 and October 27, 2004. The substance of the October 7 interview is included in the interview summary issued by the Office on October 20, 2004. On October 14, 2004 Applicants submitted a paper proposing to amend claims 37, 39, 40, and 42, and to cancel claim 38. During the October 26 and October 27 interviews, claims 37-43 were discussed. The proposed amendments to claims 37 and 39 appeared to be acceptable to the Office. The Examiner suggested further amending claim 40 to make clear that the modified candidate molecule, once identified, is then produced or manufactured on a large scale (for example, in mass quantities). Applicants amended claim 40 accordingly. For purposes of promoting prosecution only, Applicants agreed to cancel claims 41-43 and reserved the right to pursue these claims in a related application. In addition, Applicants agreed to submit a terminal disclaimer over the parent application U.S. Application Serial No. 10/922, 251 to obviate a provisional obviousness-type double patenting rejection raised by the Examiner during the October 7, 2004 interview (see interview summary).


Support for the amendments to claim 37 may be found, for example, in the paragraph bridging pages 83 and 84, the first full paragraph appearing on page 84, the fourth full paragraph appearing on page 148 and the second full paragraph appearing on page 150 of the application as originally filed. Claim 39 has been amended to correct antecedent basis. Claim 40 has been amended to correct antecedent basis and to make clear that the modified candidate molecule, once identified, is produced in a larger quantity (for example, on a commercial scale) relative to the "producing" step in claim 33. Support for the amendment can be found, for example, in the fifth full paragraph appearing on page 160 of the application as filed. Applicants believe that the amendments to claims 37, 39 and 40 introduce no new matter.

Supplemental Amendment and Response
U.S. Serial No.: 10/072,634
Page 7 of 7

In view of the enclosed terminal disclaimer and statement under 37 CFR §3.73(b) and the foregoing claim amendments, Applicants believe that the pending claims are in condition for immediate allowance. The Office is authorized to charge the fee for the Terminal Disclaimer to Deposit Account No. 20-0531.

Early favorable action is respectfully solicited. The Examiner is invited to contact the undersigned with any questions about this paper.

Respectfully submitted,



Duncan A. Greenhalgh
Attorney for Applicants
Testa, Hurwitz, & Thibeault, LLP
125 High Street
Boston, Massachusetts 02110

Date: November 5, 2004
Reg. No.: 38,678

Tel. No.: (617) 248-7317
Fax No.: (617) 248-7100

3134434